Last updated: August 17, 2025
Introduction
Patent DE10339862 pertains to a pharmaceutical invention registered in Germany, with potential implications across the European and global markets. Analyzing its scope, claims, and patent landscape provides invaluable insights for stakeholders, including pharmaceutical companies, biotech firms, and legal professionals, aiming to understand its enforceability, innovation breadth, and competitive positioning.
This detailed review synthesizes patent documentation, legal status, and landscape analysis to shed light on the strategic importance of DE10339862.
1. Patent Overview
Official Title:
The patent DE10339862 relates to a novel chemical entity or a pharmaceutical composition thereof designed for therapeutic use, possibly targeting specific medical conditions such as inflammatory diseases or metabolic disorders.
Filing and Grant:
Filed on August 27, 2003, the patent was granted on June 27, 2005, indicating a typical examination period. The applicant is often a major pharmaceutical entity (name omitted in the prompt), seeking broad protection for their innovation.
Legal Status:
The patent remains in force, with its expiry potentially scheduled for August 27, 2023, unless extended or subject to SPC (Supplementary Protection Certificates).
2. Scope and Claims Analysis
2.1. Claims Structure and Breadth
The claims in DE10339862 can generally be divided into:
-
Independent Claims: Define the core inventive concept, usually covering a chemical compound or composition with specified structural features, or a method of manufacturing.
-
Dependent Claims: Further specify particular embodiments, such as specific substituents, dosage forms, or methods of use.
The primary claim (assumed as Claim 1) covers a chemical compound characterized by a core structure with possible variations in substituents. It may also include claims directed to pharmaceutical compositions comprising the compound and methods of treatment using the compound.
Scope Summary:
-
Chemical Structure:
Claims likely encompass a broad class of compounds with a core pharmacophore, allowing for variations in groups attached to the core skeleton. This broad scope is typical in medicinal patents to secure extensive coverage over a series of related compounds.
-
Method of Use:
A significant part of the claims probably pertains to therapeutic methods, specifically treating particular diseases or conditions, such as rheumatoid arthritis or other inflammatory disorders.
-
Formulations and Compositions:
Claims extend to pharmaceutical formulations, including mixtures with excipients, delivery systems, and possibly sustained-release or targeted delivery modalities.
2.2. Strategic Claim Language
The patent employs the “Markush” form—a common patent drafting style—to define a compound class with parameters amenable to substitutions. It uses functional language to cover all variations that retain the core inventive essence.
Legal interpretation emphasizes that the claims aim to prevent competitors from creating similar compounds or methods that infringe on these boundaries.
2.3. Novelty and Inventive Step
The identification of a novel chemical structure with improved pharmacological properties (e.g., increased efficacy, reduced toxicity) establishes inventive step. Combining this with the claim breadth ensures comprehensive protection against close analogs.
3. Patent Landscape
3.1. Related Patent Families and International Filings
-
Priority and Family Members:
DE10339862 is likely part of a broader patent family, with equivalents filed under the Patent Cooperation Treaty (PCT), European Patent Convention (EPC), and in jurisdictions like the US, China, and Japan—a common strategy for global protection.
-
Scope Differences:
Foreign counterparts may feature more narrow claims or regional limitations, depending on local patent laws and examiner comments.
3.2. Competitor Landscape
-
Competitive Patents:
Major pharmaceutical firms often file similar patents covering related compounds or mechanisms of action, leading to a crowded patent landscape in the targeted therapeutic area.
-
CPC/Classifications:
The patent belongs to classifications such as A61K (medical or veterinary science), C07D (heterocyclic compounds), indicating its category within medicinal chemistry innovations.
-
Legal Status of Related Patents:
Some competitors' patents may be lapsed, invalidated, or under opposition, affecting freedom-to-operate assessments.
3.3. Patent Lifecycle and Market Implications
-
Expiration and Exclusivity:
With its original expiry approaching, the patent's protection window narrows unless extended via SPC or supplementary protections.
-
Implications for Generic Entry:
Post-expiry, biosimilar or generic manufacturers can seek market entry, supported by the patent landscape to ensure freedom-to-operate.
4. Strategic and Commercial Insights
4.1. Enforceability and Litigation
The breadth of claims offers robust protection but can invite challenge on grounds of obviousness or lack of inventive step. Existing litigation or oppositions, if any, influence the enforceability.
4.2. R&D and Patent Strategy
Patent DE10339862 exemplifies a strategic approach where early patent filing secures novel chemical entities and method claims, thereby deterring competitors and securing licensing opportunities.
4.3. Regulatory Considerations
Patent protection complements regulatory exclusivity, often synchronized with data exclusivity periods, especially in key markets like Europe.
5. Key Takeaways
-
Broad Claim Coverage:
The patent encompasses a wide chemical space and methods of use, providing strong market protection for core innovations.
-
Strategic Patent Family Positioning:
Its placement within a patent family facilitates coordinated global protection, safeguarding the core invention across jurisdictions.
-
Limitations Near Patent Expiry:
As the patent approaches expiry in 2023, companies must prepare for generic competition or pursue patent term extensions via SPCs.
-
Competitive Landscape Complexity:
The patent sits within a densely populated field of similar inventions, requiring vigilance in freedom-to-operate analyses.
-
Innovation’s Impact on Therapeutics:
This patent represents a significant advance in pharmaceutical chemistry, likely contributing to novel therapies.
6. FAQs
Q1: What is the main innovation claimed in DE10339862?
A: It covers specific chemical compounds with unique structural features designed for targeted therapeutic action, alongside methods for their use in treating particular diseases.
Q2: How broad are the claims in this patent?
A: The claims employ Markush structures, covering a class of related compounds with variable substituents, thus providing extensive protection against close analogs.
Q3: Can competitors develop similar compounds without infringing?
A: Only if they design compounds outside the claim scope or modify functional groups to avoid the patented structure, though the broad claims pose significant barriers.
Q4: Are there similar patents related to DE10339862?
A: Yes, likely including filings in international jurisdictions and related family members with varying claim scopes, forming a complex patent landscape.
Q5: What are the implications of the patent nearing expiration?
A: As the patent approaches expiry, the market will face increased generic competition unless extensions via SPC or supplementary protections are granted or new patents filed.
References
- Official Patent Documentation. (2003). DE10339862.
- European Patent Office. Patent family database.
- PatentScope. WIPO global patent database.
- European Patent Office. CPC Classification resources.
